Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
作者信息
Phillips Tycel, Brunvand Mark, Chen Andy I, Essell James, Chiappella Annalisa, Diefenbach Catherine, Cheng Ji, Ramies David, Hirata Jamie, Morschhauser Franck, Flinn Ian W
机构信息
Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Cigna Corporation, Bloomfield, Connecticut, USA.
出版信息
Am J Hematol. 2022 Jan 1;97(1):E24-E27. doi: 10.1002/ajh.26400. Epub 2021 Nov 30.
PMID:34731510
Abstract
摘要
Zotero 插件